- M3 Inc.’s forecasted operating income for the fiscal year is expected to range between 67.00 billion yen and 70.00 billion yen, falling short of the estimated 78.47 billion yen.
- Furthermore, the company’s projected net income is between 44.00 billion yen and 46.00 billion yen, also lower than the estimated 52.58 billion yen.
- On a brighter note, the company expects its net sales to amount between 268.00 billion yen and 273.00 billion yen, surpassing the estimated 262.3 billion yen.
- For the first half of the fiscal year, M3 Inc. anticipates an operating income of 28.00 billion yen, a net income of 17.50 billion yen, and net sales of 127.00 billion yen.
- The fourth quarter results were a mix, with net sales of 59.69 billion yen, marking a 7.2% year-on-year rise. However, the actual figure is slightly less than the estimated 59.74 billion yen.
- The company’s operating income for the fourth quarter dropped by 29%, at 9.42 billion yen, which is significantly lower than the estimated 15.97 billion yen.
- Similarly, the net income for the same quarter went down by 11%, recording 8.66 billion yen, which lags behind the estimated 11.19 billion yen.
- Overall, the company has gathered 4 buy ratings, 8 hold ratings, and 3 sell ratings from analysts.
- All comparisons to past results are drawn from the figures the company has previously disclosed.
M3 Inc on Smartkarma
Analyst coverage of M3 Inc on Smartkarma reveals some concerning insights. Shifara Samsudeen, ACMA, CGMA, in a research report titled “M3: Earnings Slowdown Is Inevitable,” highlighted that M3’s revenues and operating profit declined year over year in the third quarter, falling below consensus estimates. The Medical Platform reported a revenue decline, while the growth in the Overseas segment has slowed down. This downward trend in earnings raises doubts about M3’s growth prospects, with suggestions that the company may struggle to meet its full-year guidance.
Further analysis by Shifara Samsudeen in another report titled “M3: Margins Continue to Dip and Likely to Miss Full Year Guidance,” pointed out that M3’s second-quarter revenues and operating profit also fell below consensus estimates. The decline in the Medical Platform’s growth and the lack of improvement in the overseas business sector are concerning factors. The overall decrease in profits indicates potential challenges for M3 to achieve its full-year guidance, hinting at further downside risks for the company’s share price.
A look at M3 Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, M3 Inc has a mixed long-term outlook. While the company scores moderately on Value and Dividend factors with a score of 2 each, it shows stronger potential in Growth and Resilience with scores of 3 and 4, respectively. The Growth score indicates a promising future growth trajectory, while the Resilience score suggests a higher capacity to weather economic uncertainties. However, M3 Inc lags in Momentum with a score of 2, which may indicate a slower pace of market performance in the short term. Overall, the company’s focus on supplying medical information services and supporting pharmaceutical and medical equipment marketing positions it in a stable position for the long term.
M3, Inc. is a company that supplies medical information services for doctors online and facilitates the marketing efforts of pharmaceutical companies and medical equipment manufacturers. In evaluating the company’s outlook using the Smartkarma Smart Scores, M3 Inc demonstrates strengths in Growth and Resilience, suggesting potential for future expansion and a strong ability to withstand challenges. While it ranks lower on Value, Dividend, and Momentum scores, the company’s core business model and focus on the healthcare sector provide a foundation for continued stability and growth in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
